CBAY stock is under severe selling pressure after CymaBay Therapeutics Inc (NASDAQ:CBAY) reported interim data from an ongoing Phase 2b clinical trial for seladelpar.
Setback for CymaBayCalifornia-based CymaBay Therapeutics has had a setback in the Phase 2 trial with its product that was supposed to treat nonalcoholic steatohepatitis (NASH). Once the bad news spread, CBAY soon plummeted. It has emerged that the company’s product did not help in reducing liver fat significantly and a CBAY stock selloff soon got underway on Tuesday. The drug in question is seladelpar, and it has been revealed that it ...
Read The Full Article On MicroSmallCap.com
Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.
All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.